Case study from Innovation: early diagnosis in community settings

Saliva samples can be used in screening for heart failure at point of care

8 December, 2022

What is the aim?

A platform currently under development can use saliva samples and other data to inform heart failure diagnosis, risk stratification and prognosis.1 It consists of two components: a portable device that assesses four heart failure biomarkers from saliva samples, and software that combines clinical and biological data to support decision-making. The platform has the advantage of enabling rapid, non-invasive testing, causing minimal discomfort and anxiety. Only a small volume of sample is needed, and the low-cost device is also disposable.2

What has been achieved?

The project has received funding from EU Horizon 2020 and has partners in nine European countries and the US.1 Following clinical trials and health technology assessments, the aim is to implement the platform in clinical practice.


  1. Tripoliti EE, Karanasiou GS, Ioannidou P, et al. 2018. KardiaTool: An Integrated POC Solution for Non-invasive Diagnosis and Therapy Monitoring of Heart Failure Patients. 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 18-21 July 2018
  2. Tripoliti EE, Ioannidou P, Toumpaniaris P, et al. 2020. Point-of-Care Testing Devices for Heart Failure Analyzing Blood and Saliva Samples. IEEE Rev Biomed Eng 13: 17-31
Back to the Project
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca and Roche Diagnostics. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership .